Protagonist Therapeutics, Inc (PTGX): Results of Operations and Financial Condition
Protagonist Therapeutics, Inc (PTGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622272d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Protagonist Reports Second Quarter 2026 Financial Results and Provides Corporate Update ICOTYDE™ First Full Quarter of Commercial Sales with Strong Early Adoption Rusfertide NDA under Priority Review for Polycythemia Vera
How this was made
The 30-second read
Why it matters
Traders can reprice probability-weighted outcomes for rusfertide ahead of the August 2026 PDUFA decision, while also monitoring ICOTYDE’s early commercial adoption and the timing of pipeline starts in early 2027.
Market read
Primary-source disclosure of a near-term FDA decision timeline (Priority Review, PDUFA in August 2026) plus first full quarter of ICOTYDE commercial sales and updated cash position.
What to watch
The filing emphasizes milestone and royalty economics from opt-out and collaboration, but it does not provide detailed guidance or full income statement drivers beyond the reported quarter.
Background
This is Protagonist Therapeutics’ SEC Form 8-K (Item 2.02) reporting Q2 2026 financial results and a corporate update on its commercial product ICOTYDE and late-stage rusfertide NDA review status.
Ticker impact
PTGX reported Q2 2026 results and disclosed rusfertide NDA Priority Review with an August 2026 PDUFA decision plus ICOTYDE first full quarter sales.
Bias to upside volatility into the August 2026 PDUFA date, with additional support from the reported cash balance and new milestone/royalty economics.
The filing is a primary-source 8-K with concrete, time-bound regulatory and commercial milestones (Priority Review, PDUFA in August, first full quarter commercial sales) and quantified financial position (cash $849.5M as of June 30, 2026).
Market effects
Reinforces investor focus on oral peptide platforms and late-stage hematology and psoriasis assets with near-term FDA catalysts.
Limited direct regional spillover; primarily US biotech sentiment tied to FDA review timelines.
Takeda and Johnson & Johnson collaboration economics and global commercialization rights can influence broader pharma partnering sentiment.
Counterpoint
Commercial ramp for ICOTYDE is early, and the biggest value driver (rusfertide) remains contingent on FDA outcome despite Priority Review.
Key entities
- companyProtagonist Therapeutics, Inc.
Nasdaq-listed biotech reporting Q2 2026 results, ICOTYDE commercial ramp, and rusfertide NDA Priority Review with August 2026 PDUFA.
- partnerTakeda Pharmaceutical Company
Holds exclusive worldwide development and commercialization rights to rusfertide after Protagonist’s opt-out, with milestone and royalty economics described.
- partnerJohnson & Johnson
Received FDA approval for ICOTYDE, triggering a $50M milestone and supporting Protagonist’s collaboration economics.
- regulatorFDA
Completing review of rusfertide NDA under Priority Review with a PDUFA goal date in August 2026.